

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

3

Complete if Known

Application Number	10/528,577
Filing Date	March 21, 2005
First Named Inventor	Ulrich SPECK et al.
Art Unit	3763
Examiner Name	Laura A. Bouchelle
Attorney Docket Number	WEICKM-0044

U.S. PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
A1	4,502,159		03-05-85	Woodrooff et al.	
A2	4,950,256		05-21-1990	Luther et al.	
A3	6,264,624		07-24-2011	Desmond et al.	
A4	6,369,039		04-09-2002	Palasis et al.	
A5	6,419,692		07-16-2002	Yang et al.	
A6	7,611,532		11-03-2009	Bates et al.	
A7	7,750,041		07-08-2010	Speck et al.	
A8	7,811,622		10-12-2010	Bates et al.	
A9	2007/0126118		06-07-2007	Yu et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document Country Code ⁴ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
B1		DE 44 35 652	04-11-1995	Stemberger		C24
B2		DE 195 14 104	11-28-1995	Haft		C25
B3		DE 69925936	06-08-2000	Palasis et al.		C26
B4		EP 0 551 182	07-14-1993	Morris et al.		C27
B5		WO 96/20718	07-11-1995	Hart et al.		
B6		WO 96/25282	08-22-1995	Kaufmann et al.		C28

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C1	BAUMBACH ET AL., "Local Drug Delivery: Impact of Pressure, Substance Characteristics and Stenting on Drug Transfers into the Arterial Wall," Catheterization and Cardiovascular Interventions, Wiley-Liss, Inc., 1999, Vol. 47, pp. 102-105	
	C2	Series of extracts from the UK Trademarks Register, April 29, 2008	
	C3	IUPAC, Compendium of Chemical Terminology (1987)	
	C4	Table of General Chemical Information, October 12, 2009	

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/528,577
(Use as many sheets as necessary)		Filing Date	March 21, 2005
Sheet	2	First Named Inventor	Ulrich SPECK et al.
	of 3	Art Unit	3763
		Examiner Name	Laura A. Bouchelle
		Attorney Docket Number	WEICKM-0044
NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	C5	Product information DIOR balloon catheter of Eurocor GmbH, October 1, 2008	
	C6	KALBITZ ET AL., "Modulation der Wirkstoffpenetration in die Haut," Pharmazie, 1996, Vol. 51, pp. 619-637	
	C7	P. MACKE CONSIGNY ET AL., "Local Delivery of an antiproliferative drug with use of hydrogel-coated angioplasty balloons," J. Vasc. Interv. Radiol., 1994, Vol. 5, pp. 553-560	
	C8	DRACHMANN ET AL., "Neointimal thickening after stent delivery of paclitaxel: Change in composition and arrest of growth over six month," J. Am. Coll. Cardiol., 2000, Vol. 36, pp. 2325-2332	
	C9	Abstracts From the 70 th Scientific Sessions, Circulation, October 21, 1997, 96 Suppl. 1: 1-288	
	C10	VAN BELLE, E. ET AL., "Passivation of metallic stents after arterial gene transfer of phVEGF165 inhibits thrombus formation and intimal thickening," J. Am. Coll. Cardiol., 1997, Vol. 29, pp. 1371-1379	
	C11	Versuchsbeschreibungen (D44) ("Description of experiments"), July 9, 2010	
	C12	Affidavit (D46), July 9, 2010	
	C13	Final Report Study ACL435-43 (D47), May 14, 2009	
	C14	Summary Data Biotronik SE & Co. KG (D48), July 9, 2010	
	C15	Submission BpatG (Ceramide Balloon Catheter) MLA HLA (D49), July 9, 2010	
	C16	German Translation of "Gericht zu's Gravenhage, 245392/HA ZA 05-2016 (D49A)	
	C17	Press release of 17 January 2007 regarding patent infringement suit (D49C)	
	C18	MORTIMER, C. ET AL., Basiswissen Chemie (excerpt) (1987) (D50)	
Examiner Signature			Date Considered

*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

3

of

3

Complete if Known

Application Number	10/528,577
Filing Date	March 21, 2005
First Named Inventor	Ulrich SPECK et al.
Art Unit	3763
Examiner Name	Laura A. Bouchelle
Attorney Docket Number	WEICKM-0044

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C19	Summons to attend Oral Proceedings dated June 4, 2010 (D51)	
	C20	GERSHICK ET AL., "Inhibition of Restenosis with a Paclitaxel-Eluting, Polymer-Free Coronary Stent: The European evaluation of paclTaxel Eluting Stent (ELUTES) Trial." Circulation, 2004, Vol. 109, pp. 487-493	
	C21	INDOLFI ET AL., "Smooth Muscle Cell Proliferation Is Proportional to the Degree of Balloon Injury in a Rat Model of Angioplasty." Circulation, 1995, Vol. 92, pp. 1230-1235	
	C22	MANDERSON ET AL., "Balloon Catheter Injury to Rabbit Carotid Artery. I. Changes in smooth muscle phenotype." Arteriosclerosis, 1989, Vol. 9, pp. 289	
	C23	Data Supplement to R. Charles et al., Circulation Research, 2000, Vol. 87, pp. 282	
	C24	STEMBERGER, AXEL DR., "Coating for bio-material to be used e.g. as sutures." Retrieved from Espacenet on November 19, 2010; English Abstract of DE 4435652	
	C25	STEMBERGER, AXEL, DR., "Coating for bio-material insertable into the bloodstream or tissue of the human body." Retrieved from Espacenet on November 19, 2010; English Abstract of DE 19514104	
	C26	STEMBERGER, AXEL, DR., "High efficiency local drug delivery." Retrieved from Espacenet on November 19, 2010; English Abstract of DE 69925936	
	C27	MORRIS, R. E. ET AL., "Method of treating hyperproliferative vascular disease using rapamycin, eventually in combination with mycophenolic acid." Retrieved from Espacenet on November 19, 2010; English Abstract of EP0551182	
	C28	KAUFMANN, G. ET AL., "Process for producing a plastic cladding component and cladding component produced especially by said process." Retrieved from Espacenet on November 19, 2010; English Abstract of WO9625282	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.